China
· Delayed Price · Currency is CNY Anhui Anke Biotechnology (Group) Statistics
Total Valuation
Anhui Anke Biotechnology (Group) has a market cap or net worth of CNY 15.42 billion. The enterprise value is 14.40 billion.
| Market Cap | 15.42B |
| Enterprise Value | 14.40B |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | May 27, 2024 |
Share Statistics
Anhui Anke Biotechnology (Group) has 1.67 billion shares outstanding. The number of shares has increased by 0.64% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.67B |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | +4.41% |
| Owned by Insiders (%) | 37.87% |
| Owned by Institutions (%) | 9.51% |
| Float | 1.03B |
Valuation Ratios
The trailing PE ratio is 19.63 and the forward PE ratio is 14.63. Anhui Anke Biotechnology (Group)'s PEG ratio is 0.81.
| PE Ratio | 19.63 |
| Forward PE | 14.63 |
| PS Ratio | 5.56 |
| PB Ratio | 4.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.88 |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.81 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.51, with an EV/FCF ratio of 24.17.
| EV / Earnings | 18.40 |
| EV / Sales | 5.21 |
| EV / EBITDA | 15.51 |
| EV / EBIT | 17.61 |
| EV / FCF | 24.17 |
Financial Position
The company has a current ratio of 3.20, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.20 |
| Quick Ratio | 2.66 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.09 |
| Interest Coverage | 300.63 |
Financial Efficiency
Return on equity (ROE) is 20.21% and return on invested capital (ROIC) is 12.86%.
| Return on Equity (ROE) | 20.21% |
| Return on Assets (ROA) | 10.67% |
| Return on Capital (ROIC) | 12.86% |
| Revenue Per Employee | 926,205 |
| Profits Per Employee | 262,068 |
| Employee Count | 2,986 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.82% in the last 52 weeks. The beta is 0.56, so Anhui Anke Biotechnology (Group)'s price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -8.82% |
| 50-Day Moving Average | 8.75 |
| 200-Day Moving Average | 9.12 |
| Relative Strength Index (RSI) | 52.00 |
| Average Volume (20 Days) | 34,753,644 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Anhui Anke Biotechnology (Group) had revenue of CNY 2.77 billion and earned 782.53 million in profits. Earnings per share was 0.47.
| Revenue | 2.77B |
| Gross Profit | 2.15B |
| Operating Income | 817.71M |
| Pretax Income | 850.43M |
| Net Income | 782.53M |
| EBITDA | 921.05M |
| EBIT | 817.71M |
| Earnings Per Share (EPS) | 0.47 |
Balance Sheet
The company has 1.27 billion in cash and 55.76 million in debt, giving a net cash position of 1.21 billion or 0.73 per share.
| Cash & Cash Equivalents | 1.27B |
| Total Debt | 55.76M |
| Net Cash | 1.21B |
| Net Cash Per Share | 0.73 |
| Equity (Book Value) | 4.13B |
| Book Value Per Share | 2.28 |
| Working Capital | 1.54B |
Cash Flow
In the last 12 months, operating cash flow was 748.05 million and capital expenditures -152.31 million, giving a free cash flow of 595.74 million.
| Operating Cash Flow | 748.05M |
| Capital Expenditures | -152.31M |
| Free Cash Flow | 595.74M |
| FCF Per Share | 0.36 |
Margins
Gross margin is 77.62%, with operating and profit margins of 29.57% and 28.29%.
| Gross Margin | 77.62% |
| Operating Margin | 29.57% |
| Pretax Margin | 30.75% |
| Profit Margin | 28.29% |
| EBITDA Margin | 33.30% |
| EBIT Margin | 29.57% |
| FCF Margin | 21.54% |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 2.67%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 2.67% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 4 |
| Payout Ratio | 52.83% |
| Buyback Yield | -0.64% |
| Shareholder Yield | 2.04% |
| Earnings Yield | 5.09% |
| FCF Yield | 3.86% |
Stock Splits
The last stock split was on May 14, 2021. It was a forward split with a ratio of 1.2.
| Last Split Date | May 14, 2021 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
Anhui Anke Biotechnology (Group) has an Altman Z-Score of 13.02.
| Altman Z-Score | 13.02 |
| Piotroski F-Score | n/a |